PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

To identify a group of patients who might benefit from the addition of weekly paclitaxel to conventional anthracycline-containing chemotherapy as adjuvant therapy of node-positive operable breast cancer. The predictive value of PAM50 subtypes and the 11-gene proliferation score contained within the...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., Bernard, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608881/
https://www.ncbi.nlm.nih.gov/pubmed/23423445
http://dx.doi.org/10.1007/s10549-013-2416-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608881/
https://www.ncbi.nlm.nih.gov/pubmed/23423445
http://dx.doi.org/10.1007/s10549-013-2416-2

Ejemplares similares